trastuzumab,fulvestrant,tucatinib
seagen
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'basket study', 'tucatinib']
phase ii basket study of tucatinib/trastuzumab - all pts w mbtc and negative central her2 testing (regardless of testing method) were nonresponders. #asco23 
Hematology/Oncology Fellow @ClevelandClinic. Interested in GI oncology. Internist via @CCF_IMCHIEFS. IUSM graduate. She/her. Tweets are my own.